Preclinical pharmacology of a lipophenol in a mouse model of light-induced retinopathy
Nicolas Taveau, Aurélie Cubizolle, Laurent Guillou, Nicolas Pinquier, Espérance Moine, David Cia, Vasiliki Kalatzis, Joseph Vercauteren, Thierry Durand, Céline Crauste, Philippe Brabet
Abstract
Abstract Environmental light has deleterious effects on the outer retina in human retinopathies, such as ABCA4 -related Stargardt’s disease and dry age-related macular degeneration. These effects involve carbonyl and oxidative stress, which contribute to retinal cell death and vision loss. Here, we used an albino Abca4 −/− mouse model, the outer retina of which shows susceptibility to acute photodamage, to test the protective efficacy of a new polyunsaturated fatty acid lipophenol derivative. Anatomical and functional analyses demonstrated that a single intravenous injection of isopropyl-phloroglucinol-DHA, termed IP-DHA, dose-dependently decreased light-induced photoreceptor degeneration and preserved visual sensitivity. This protective effect persisted for 3 months. IP-DHA did not affect the kinetics of the visual cycle in vivo or the activity of the RPE65 isomerase in vitro. Moreover, IP-DHA administered by oral gavage showed significant protection of photoreceptors against acute light damage. In conclusion, short-term tests in Abca4 -deficient mice, following single-dose administration and light exposure, identify IP-DHA as a therapeutic agent for the prevention of retinal degeneration.